retatrutide fat loss trial Weight with as compared to currently licenced obesity A New Obesity Drug Delivered

A few things to note about this study is that there was no significant increase in risk for people after three years on these medications

Monitor your energy: Note down when you feel most tired to see if it correlates with your meal timing

Ill continue with the meds and hopefully continue a gradual weight loss that I can nudge along with adjusted diet habits and consistent exercise

Kovacic P, Edwards WD, Ming G

Semaglutide and Tirzepatide are two widely studied compounds in laboratory research focused on incretin signaling and metabolic pathway regulation

GLP-1 receptor agonists are a class of medications originally developed and licensed for the treatment of type 2 diabetes mellitus, with some formulations also approved by the MHRA for weight management in adults with obesity or overweight with weight-related comorbidities, under specialist services as per NICE guidance (TA875)